Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Mitsubishi Tanabe Yields 3.9% Sales Increase in Q1 on Radicava’s Overseas Growth
Mitsubishi Tanabe’s April-June group sales grew 3.9% from a year ago, buoyed by the growth of the amyotrophic lateral sclerosis (ALS) treatment Radicava (edaravone) in overseas markets in a rebound from the previous year when fewer clinic visits were seen…
To read the full story
Related Article
- Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
May 15, 2023
- Mitsubishi Tanabe Incurs 33 Billion Yen Operating Loss on Medicago Shutdown
February 8, 2023
- Mitsubishi Tanabe’s Core Operating Profit Leaps 60.2% in 1st Half on Priority Products, Overseas Sales
November 10, 2022
- Mitsubishi Tanabe’s Q1 Sales Rise 2.9% on Growth in Japan
August 4, 2022
- Mitsubishi Tanabe Incurs Operating Loss for 3 Years Running, Logs Write-Down on OA Drug
May 16, 2022
- Mitsubishi Tanabe’s 9 Month Sales Rise Fueled by Strong Growth in Stelara
February 4, 2022
BUSINESS
- Pfizer Files Migraine Drug Rimegepant in Japan
November 28, 2024
- Dermatologist Hails Bimzelx as New Option for HS: UCB Seminar
November 27, 2024
- Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
- Eisai, NCNP Tie Up for APOE Genetic Testing Research Sponsored by AMED
November 27, 2024
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…